Robot Assisted Minimally Invasive Treatment Versus Conventional Surgery for FFP3-4 Fragility Fractures of the Pelvis in Elderly Patients

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age60+
SponsorJunbo Liang

About this trial

This prospective randomized controlled trial aims to compare the efficacy and safety of robot assisted minimally invasive treatment versus conventional surgery in elderly patients with FFP3-4 fragility fractures of the pelvis. Eligible patients will be stratified according to FFP classification and randomly assigned in a 1:1 ratio to receive either robot assisted minimally invasive fixation or conventional surgical treatment. Primary and secondary outcomes include pain relief, early mobilization, functional recovery, perioperative complications, venous thromboembolism events, laboratory parameters, imaging outcomes, and healthcare resource utilization. The study aims to provide evidence for optimizing surgical treatment strategies in elderly patients with unstable pelvic fragility fractures.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥ 60 years

Low energy trauma

Diagnosis of osteoporosis

Diagnosis of FFP3 or FFP4 fragility fractures of the pelvis

Disqualifiers

Severe open injury or skin infection at the surgical site

Hemodynamic instability preventing anesthesia or surgery

Severe psychiatric disorders or dementia

Severe obesity affecting imaging quality

Trial design

Design model

Parallel

Treatments tested in this trial

  • Robot Assisted Minimally Invasive Fixation

    Procedure/Surgery

    Robot assisted minimally invasive fixation is performed using robotic navigation assisted percutaneous screw placement for stabilization of unstable pelvic fragility fractures.

  • Conventional Open Fixation

    Procedure/Surgery

    Conventional open reduction and internal fixation for FFP3-4 pelvic fragility fractures performed without robotic assistance.

Treatment groups

88 Participants
are divided into 2 treatment groups
Group A: Robot Assisted Minimally Invasive Treatment GroupExperimental treatment 1 intervention
Group B: Conventional Surgery GroupActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Visual Analog Scale (VAS) for Pain

Visual Analog Scale (VAS) for pain. Scores range from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate worse pain severity.

Time frame
At 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 12 hours, day 1, day 2, day 3, 2 weeks, 1 month, 2 months, 3 months, 6 months, and 1 year after treatment
2

Majeed Pelvic Function Score

The Majeed Pelvic Function Score is used to evaluate functional recovery after pelvic fracture treatment. Scores range from 0 to 100, with higher scores indicating better functional outcomes and quality of life.

Time frame
At day 3, 2 weeks, 1 month, 2 months, 3 months, 6 months, and 1 year after treatment

Secondary outcomes

1

EuroQol 5-Dimension 3-Level Questionnaire

Health related quality of life assessed using the EuroQol 5-Dimension 3-Level Questionnaire (EQ-5D-3L). The EQ-5D index score ranges from values below 0 (health states considered worse than death) to 1.0 (full health). Higher scores indicate better health related quality of life.

Time frame
At day 3, 2 weeks, 1 month, 2 months, 3 months, 6 months, and 1 year after treatment
2

Fracture Healing

Time frame
At day 3, 2 weeks, 1 month, 2 months, 3 months, 6 months, and 1 year after treatment
3

Complication

Time frame
From treatment initiation to 1 year follow up
4

Opioid Consumption

Assessment of cumulative opioid consumption during hospitalization

Time frame
Time Frame: Postoperative Days 0-3

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Junbo Liang

Lead sponsor

Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University

Sponsor institution

This trial is not recruiting at the moment. You can still explore other options: